Follow us on Twitter
twitter icon@FreshPatents


Factor patents

      

This page is updated frequently with new Factor-related patent applications.




 Wearable device authentication patent thumbnailWearable device authentication
A wearable device is used to authenticate a user into a user account at a user device of the user. In particular, the wearable device may include a sensor configured to detect a body chemistry of the user.
Paypal, Inc.


 Apparatus and methods for ground plane loading of antennae patent thumbnailApparatus and methods for ground plane loading of antennae
High radiation-efficiency antenna apparatus, and methods of manufacturing and utilizing the same. In one embodiment, an intentionally “loaded” antenna configuration is used within a handheld mobile device (e.g., cellular telephone) in order to enhance radiation efficiency for a given size antenna, or conversely allow for a reduction in size of the antenna for the same electrical performance.
Pulse Finland Oy


 Self-adaptive antenna systems for electronic devices having multiple form factors patent thumbnailSelf-adaptive antenna systems for electronic devices having multiple form factors
An electronic device is described that is configurable to be transitioned from a first operating mode having a first form factor to a second operating mode having a second form factor. The electronic device includes a first device portion and a second device portion that is connected to the first device portion.
Microsoft Technology Licensing, Llc


 Small form factor pluggable unit with wireless capabilities patent thumbnailSmall form factor pluggable unit with wireless capabilities
The present subject matter relates to one or more devices, systems and/or methods for providing wireless telecommunication services. A small form factor pluggable unit (sfp) incorporates wireless capabilities, and includes an integrated or an external antenna.

 Modulation of growth hormone receptor expression and insulin-like growth factor expression patent thumbnailModulation of growth hormone receptor expression and insulin-like growth factor expression
Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-i (igf-i). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor.
Antisense Therapeutics Limited


 Expansion and engraftment of stem cells using notch 1 and/or notch 2 agonists patent thumbnailExpansion and engraftment of stem cells using notch 1 and/or notch 2 agonists
The present disclosure provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, the methods comprising culturing the precursor cells in the presence of a notch 1 agonist, notch 2 agonist or notch 1 agonist and notch 2 agonist (and, in particular embodiments, one or more growth factors) that support the proliferation but not differentiation of the non-terminally differentiated cells. The present disclosure further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a notch 1 agonist, notch 2 agonist or notch 1 agonist and notch 2 agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type.
Fred Hutchinson Cancer Research Center


 Method of manufacturing or differentiating mammalian pluripotent stem cellsor progenitor cells using a hollow fiber bioreactor patent thumbnailMethod of manufacturing or differentiating mammalian pluripotent stem cellsor progenitor cells using a hollow fiber bioreactor
The present disclosure provides a method of manufacturing and differentiating mammalian stern cells, and in one embodiment human induced pluripotent stern cells (ipsc), e.g., manufacturing neuron progenitors, e.g., derived from ipsc, on a large scale by the use of an automated hollow fiber reactor system. In one embodiment, human ipsc that can be differentiated into cardiomyocytes or neuron progenitors are provided.
Stemonix Inc.


 Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics patent thumbnailInhibitors of late sv40 factor (lsf) as cancer chemotherapeutics
The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. Heptacellular carcinoma.
Trustees Of Boston University


 Trka kinase inhibitors, compositions and methods thereof patent thumbnailTrka kinase inhibitors, compositions and methods thereof
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.. .
Merck Sharp & Dohme Corp.


 Water-soluble electrolyzed/hydrolyzed clinoptilolite fragments and nutraceutical, pharmaceutical, and environmental products based thereon patent thumbnailWater-soluble electrolyzed/hydrolyzed clinoptilolite fragments and nutraceutical, pharmaceutical, and environmental products based thereon
Methods and processes are provided to make clinoptilolite into a water-soluble hydrolyzed form with electrolytes suitable for various administration routes for use in the detoxification and rejuvenation in environment arena, nutraceutical arena, and pharmaceutical arena this process includes oral, topical, tablet, pill formulas, biotech delivery and intravenous. Absorption of water-soluble hydrolyzed clinoptilolite fragments can aid in detoxification by binding to heavy metals, viruses and environmental toxins and can reduce reactive oxygen species and inflammation related to metals.
Entox Solutions Llc


Water-soluble electrolyzed/solvolyzed clinoptilolite fragments and nutraceutical, pharmaceutical, and environmental products based thereon

Methods and processes are provided to make clinoptilolite into a water-soluble solvolyzed form with electrolytes suitable for various administration routes for use in the detoxification and rejuvenation in environment arena, nutraceutical arena, and pharmaceutical arena this process includes oral, topical, tablet, pill formulas, biotech delivery and intravenous. Absorption of water-soluble solvolyzed clinoptilolite fragments can aid in detoxification by binding to heavy metals, viruses and environmental toxins and can reduce reactive oxygen species and inflammation related to metals.
Entox Solutions Llc

Inter-poly connection for parasitic capacitor and die size improvement

The present disclosure relates to micro-electromechanical system (mems) package that uses polysilicon inter-tier connections to provide for a low parasitic capacitance in mem device signals, and a method of formation. In some embodiments, the mems package has a cmos substrate with one or more semiconductor devices arranged within a semiconductor body.
Taiwan Semiconductor Manufacturing Co., Ltd.

Nanofiber paste for growth factor delivery and bone regeneration

Provided herein are compositions comprising a composite of peptide amphiphiles and biocompatible particles and methods of use thereof for treatment of bone and/or tissue defects. In particular, compositions comprise a slurry paste of a peptide amphiphile nanofiber solution mixed with solid biocompatible particles, and find use in tissue/bone regeneration, growth factor delivery, and/or cell delivery..
Northwestern University

Cytokine-chitosan bioconjugates and methods of using the same

Compositions including chitosan covalently linked to a cytokine or growth factor are provided herein. The compositions can be used to produce pharmaceutical compositions and can be used in methods of treating a variety of diseases or disorders.
The Board Of Trustees Of The University Of Arkansas

Single-dose administration of factor viia

The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a factor viia equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg factor viia equivalent..
Novo Nordisk Healthcare Ag

Use of long-acting human recombinant soluble tumor necrosis factor a receptor in the preparation of drugs for preventing and treating severe liver injury on chronic liver disease

The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis α receptor (hustnfr) and belongs to the gene engineering technology and gene function application field. This invention uses type i or type ii long-acting hustnfr (lhustnfr) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models.

Crest factor reduction in a radio transmitter

Crest factor reduction techniques and apparatus provide good performance while reducing the impact to power consumption and implementation cost. An example method begins with identifying multiple non-overlapping and separated signal segments in a signal made up of a sequence of digital signal values, each identified segment being an interval in which at least one the digital signal values exceeds a predetermined threshold.
Telefonaktiebolaget L M Ericsson (publ)

High voltage compact fuse assembly with magnetic arc deflection

Fuse assemblies in the form of fuse blocks and fuse holders include embedded permanent magnet arc suppression features that facilitate higher voltage operation of fusible circuit protection without increasing the size of the fuse assemblies. The embedded magnets apply an external magnetic field upon an overcurrent protection fuse and produce an arc deflection force to enhance arc quenching capability of the fuse without increasing its form factor..
Cooper Technologies Company

Adaptive thermal control and power budget

A method, an apparatus, and a computer program product for performance management are provided. The apparatus may be an electronic device.
Qualcomm Incorporated

Polynucleotides and polypeptides in plants

The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
Mendel Biotechnology, Inc.

Synthetic antibody mimic peptides

The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (pdcs) comprising the mimic peptides disclosed herein.
Formurex, Inc.

Chimeric fibroblast growth factor 19 proteins and methods of use

The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University

Novel fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof

The present invention relates to a novel fusion protein comprising the transcription modulation domain of the transcription factor nf-κb subunit p65 and a protein transduction domain and to the use thereof. The fusion protein of the present invention has the effects of inhibiting the transcription of nf-κb and il-2 by competitive inhibition and inhibiting the lps-induced secretion of inflammatory cytokines and also inhibiting the production of il-2, ifn-γ, il-4, il-17a and il-10 in splenocytes, and thus is effectively used as a composition for the prevention or treatment of a disease related to nf-κb overactivity..

Peptide ligands for hepatic stellate cells

Methods and compositions for identifying and using polypeptides that target hepatic stellate cells are described. Embodiments include a targeting composition that may include one or more polypeptides including an amino acid sequence that binds to an insulin-like growth factor 2 receptor.

Trail enhancers for the selective killing of cancer cells

The invention is directed to methods of inducing apoptosis, arresting cell cycle, or inhibiting cellular proliferation, or any combination thereof, in a tumor cell, by administration of an effective amount of an n-acyl homoserine lactone analog (ahl), optionally in conjunction with a tumor modulating agent such tumor necrosis factor (tnf) related apoptosis inducing ligand (trail) to the patient. Novel bioactive analogs of an n-acyl homoserine lactone are also provided..
The Scripps Research Institute

Payload estimation using electric power steering signals

A payload estimation system and a method for estimating payload estimation using electric power steering (eps) signals are provided. In certain embodiments, the aspects of the invention may include: receiving, by a payload detection module, multiple eps signals to generate an additional axle load factor, determining, by a blend factor table, a load blend factor according to the additional axle load factor, generating, by a first multiplier, a blended nominal base assist signal by combining the load blend factor and a handwheel torque signal processed by a nominal base assist module, generating, by a second multiplier, a blended highload base assist signal by combining the load blend factor and the handwheel torque signal processed by a highload base assist module, and combining, by a merge module, the blended nominal base assist and the blended highload base assist to generate a motor torque command for the eps system..
Steering Solutions Ip Holding Corporation

Protease resistant growth factor formulations for chronic wound healing

A formulation and method of treating chronic wounds is presented. The formulation uses two different fusion peptides, one of which incorporates an elastase resistant peptide, to preserve the bioactivity of different functional peptides and growth factors in chronic wounds..
University Of South Florida

Compositions and methods for targeting nuclear import shuttles and treating inflammatory disorders

The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (ntm) and/or at least one importin alpha-selective ntm, and/or at least one importin alpha-specific ntm, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation..
Vanderbilt University

Compositions and methods that target olfactory receptors for regulation of breathing

The olfactory receptor olfr78/or51e2 is shown to be expressed in the carotid body and to control breathing responses regulated by acute hypoxia sensing. Activation of olfr78/or51e2 increases breathing, while inhibitors of the receptor can counteract this activity.
The Board Of Trustees Of The Leland Stanford Junio

Small form-factor cryptographic expansion device

A cryptographic expansion device that can be attached to a communication component of a communication device to enable the communication device to perform cryptographic operations on communications sent to and from the communication device is described. The cryptographic expansion device can be a small-form factor cryptographic expansion device that can be used with a small-form factor communication component such as a micro-sim (subscriber identity module) card.

Alternative form factor for financial inclusion

According to some embodiments, apparatus and methods are provided comprising a connector attachment including a housing, wherein the connector attachment is selectively connectable to a mobile device; and a first token stored within the connector attachment, wherein the first token is operative to execute a transaction with a second token. Numerous other aspects are provided..
Mastercard International Incorporated

Systems, devices, and methods for interacting with content displayed on head-mounted displays

Systems, devices, and methods that enable sophisticated and inconspicuous interactions with content displayed on a head-mounted display are described. A head-mounted display includes an eye-tracker and the user also carries/wears a wireless portable interface device elsewhere on their body, such as a ring.
Thalmic Labs Inc.

Method and negating effects of continuous introduction of risk factors in determining the health of a process control system

Negating effects of continuous introduction of risk in scoring the health of a process control system includes automatically and periodically assessing a risk for each of the process control systems, calibrating the center of a health score scale to the average risk assessments, and scoring the health of each process control system within the health score scale according to a nonlinear scale applied to the risk assessment. Introduction of a risk factor to a process control system increases the risk assessment, and elimination of a risk factor decreases the risk assessment.
Fisher-rosemount Systems, Inc.

Scaling fixed-point fast fourier transforms in radar and sonar applications

Present disclosure describes an improved scaling mechanism for a multi-stage fixed-point fft algorithm used to process signals received by radar or sonar systems. Proposed scaling includes scaling an output of every pair of consecutive butterfly stages of the fft algorithm by a scaling factor equal to two times of the inverse of a growth factor for the pair of consecutive butterfly stages for the fft algorithm for a purely complex exponential input signal.
Analog Devices, Inc.

Multi-sensor

Various implementations relate generally to a multi-sensor device. Some implementations more particularly relate to a multi-sensor device including a ring of radially-oriented photosensors.
View, Inc.

Aav vectors for vascular gene therapy in coronary heart disease and peripheral ischaemia

The invention relates to the provision of a gene therapy for coronary heart disease and peripheral ischemia in mammals. One embodiment is an adeno-associated viral vector (aav vector) comprising a first gene encoding a myocardin-related transcription factor a (mrtf-a).

Method of therapy and diagnosis of endothelial dysfunction

The invention discloses a method of therapy of endothelial dysfunction, by administering microrna let-7g to a subject in need, wherein the microrna let-7g inhibits smad2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis.. .
Kaohsiung Medical University

Coagulation factor vii polypeptides

The present invention relates to modified coagulation factor vii polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment..
Novo Nordisk Healthcare Ag

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

The invention relates generally to variant activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically binds to epidermal growth factor receptor (egfr), and to methods of making and using these variant anti-egfr activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.

Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to tumor necrosis factor-alpha. It further relates to single domain antibodies that are camelidae vhhs.
Ablynx N.v.

Soluble tumor necrosis factor receptor treatment of medical disorders

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of tnfα by administering a tnfα antagonist, such as recombinant tnfr:fc.. .
Immunex Corporation

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders

The present invention relates to chimeric proteins that include an n-terminus coupled to a c-terminus, where the n-terminus includes an n-terminal portion of fibroblast growth factor 21 (“fgf21”) and the c-terminus includes a c-terminal portion of fibroblast growth factor 19 (“fgf19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased fgf21-βklotho-fgf receptor complex formation, methods of causing increased fgf21 receptor agonist-βklotho-fgf receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βklotho-fgf receptor complex involving the use of chimeric proteins of the present invention..
New York University

Macrocycles with aromatic p2' groups as factor xia inhibitors

The present invention provides compounds of formula (i): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.
Bristol-myers Squibb Company





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.4038

file didn't exist2763

479197 - 0 - 54